Company Overview
Coeptis Therapeutics Holdings, Inc. operates as a biopharmaceutical company that focuses on developing cell therapy platforms designed to treat cancer, autoimmune conditions, and infectious diseases. The firm is categorized within the Healthcare sector and specifically functions in the Biotechnology industry, which typically involves high-risk, high-reward research and development activities with long timelines to commercialization. As of the latest data, the company maintains a market capitalization of $66.46M and generates an annual revenue of $1.36M while employing just four individuals. The combination of a market cap in the mid-$60 million range and revenue under $2 million indicates that Coeptis is a micro-cap entity with a very small operational footprint relative to its valuation, suggesting that the market price largely reflects the value of its intellectual property and pipeline potential rather than current cash-flowing operations.
Financial Health
The company reported a revenue of $1.36M over the trailing twelve months, yet recorded a net income of $-11,917,015 and an EBITDA of $-11,862,286. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure dominated by non-revenue expenses, likely including extensive research and development costs, administrative overhead, and potentially stock-based compensation common in biotech startups. Free cash flow stands at $-3,030,945, which indicates that the company is currently burning cash to fund its operations and development efforts, implying a lack of immediate financial flexibility to sustain growth without external capital injections. Margin analysis shows a Gross Margin of 86.7%, which is healthy for a biotech firm with high-margin product sales or licensing, but this is offset by an Operating Margin of -230.6% and a Profit Margin of 0.0%, highlighting that operating expenses are far exceeding the revenue generated. On the balance sheet, the company holds $6.35M in cash against $268,875 in debt, resulting in a Debt to Equity ratio of 1.91, which suggests a leveraged position given the small equity base despite the absolute debt amount being relatively low. Liquidity is supported by a Current Ratio of 4.16, indicating that the company has more than four times the current assets necessary to cover its short-term liabilities, providing a buffer against immediate solvency risks. Return on Equity is -136.9% and Return on Assets is -65.1%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than profits, a typical characteristic of early-stage development companies but one that signals a negative return profile at this specific moment.
Valuation Assessment
The trailing P/E Ratio is listed as N/A due to the lack of earnings, while the Forward P/E is reported at -62.82, a metric that implies the market is pricing in future earnings that are not yet realized or are expected to be negative in the near term. The Price to Book ratio is 4.53, indicating that the market is valuing the company at a significant premium over its net book value, which often reflects confidence in the value of the company's intangible assets and pipeline rather than its tangible balance sheet. Alternative valuation metrics show a Price to Sales ratio of 48.76 and an EV/EBITDA of -5.13, suggesting that the valuation is heavily dependent on revenue multiples rather than earnings power, a common approach for companies with no current profitability. The 52-week high is $21.41 and the 52-week low is $6.26, meaning the current trading price sits at a level that has experienced significant volatility within this specific range over the past year. The Beta is -0.47, a unique and negative value that suggests the stock's price movements are inversely correlated to the broader market, moving in the opposite direction with less volatility than the average market stock, which presents a distinct risk profile for portfolio diversification.
Growth & Income
Revenue Growth and Earnings Growth for the year over year are both listed as N/A, indicating that the company does not have sufficient historical data to calculate a meaningful year-over-year growth rate or that the growth rates are currently undefined due to the nature of the business stage. Since the company is not a dividend payer, the dividend yield is N/A and the Payout Ratio is 0.0%, which means the company reinvests all available resources and any potential earnings directly back into research, development, and operational expansion rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current profitability and dividend generation, relying entirely on the potential future success of its cell therapy platforms to drive future value creation.